The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...

Although fluid restriction is standard first-line treatment, it is often ineffective in patients with hyponatremia and syndrome of inappropriate antidiuresis (SIAD).

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA ...

Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• ...

This one-day decline has now brought NVO’s twelve-month return to -56%. The pertinent question: Is this a buying opportunity?

High-protein meals are easy to find at most fast food restaurants, but it’s smart to choose options that are moderate in calories and saturated fat and include some fiber. Since many fast food items ...

As CGRP-targeted therapies move into wider use, new data are beginning to clarify their role in special populations, the value of switching agents when one fails, and their long-term vascular safety.

The FDA has approved the first all-oral, fixed-duration first-line regimen for treatment of chronic lymphocytic leukemia and ...

A Little Rock man who dropped a pistol off at a Conway gun shop and was subsequently charged with being a felon in possession of a firearm was sentenced to time served by a judge who told him, "you're ...

Researchers find long-term exposure to mining pollution is associated with significant cognitive impairment in Peruvian ...

Dupilumab was safe and effective for the treatment of patients with severe AD who were aged 6 months to 5 years in a real-world study.

Three drugs that inhibit the immunoglobulin G (IgG) neonatal fragment crystallizable receptor (FcRn) were approved to treat ...